Disclosures for "Development and internal validation of a clinical risk score to predict incident renal and pulmonary tumors in people with tuberous sclerosis complex")
-
Mr. Loubert has nothing to disclose.
-
Dr. House has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. House has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Baxter. Dr. House has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Canadian Medical Protective Association.
-
Dr. Larochelle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Novartis, Sanofi-Genzyme, Alexion, EMD-Serono, FIND therapeutics, Actelion. The institution of Dr. Larochelle has received research support from Université de Montréal-CHUM.
-
Dr. Major has nothing to disclose.
-
The institution of Dr. Keezer has received research support from UCB . The institution of Dr. Keezer has received research support from Eisai. The institution of Dr. Keezer has received research support from TD Bank. The institution of Dr. Keezer has received research support from Savoy Foundation. The institution of Dr. Keezer has received research support from TSC Alliance. The institution of Dr. Keezer has received research support from Quebec Bio-imaging Network. The institution of Dr. Keezer has received research support from Canadian Institutes of Health Research. The institution of Dr. Keezer has received research support from Fonds de Recherche Québec Santé.